In 2024, the company forged new partnerships with three of the largest, global pharmaceutical companies in the world, realizing a total of 10 partnerships with leading life science companies. Viz.ai ...

Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

The three-year partnership is another example of Vertex’s interest in improving on Casgevy, its CRISPR medicine for sickle cell and beta thalassemia.

Results from a study called Mariposa found a regimen of Rybrevant and Lazcluze helped patients with a common form of advanced ...

The startup is developing macrocyles, which share strengths of both small molecules and biologics, as oral medicines against ...

By the end of March, the regulator could clear a highly anticipated pain drug from Vertex and a heart drug that’s critical to Alnylam’s future.

Jan. 4, 2025 – Jan. 30, 2025 • New york, American Samoa ...

The well-funded biotech lost most of its value after its drug flunked a late-stage trial. One analyst described the results ...

The agency’s main drug review office cleared 50 novel medicines last year, short of 2018’s record total but on the higher end ...

Sangamo shares fell on Pfizer’s decision to hand back rights to a hemophilia gene therapy. Elsewhere, Novartis got ...

Expected readouts in diabetes, cancer and depression headline a series of study results that could help the biotechnology ...